Project Grant HT94252310254
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$480K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
The University of Minnesota will leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors under a $548,892 project grant from the Defense Health Agency. The grant was awarded on August 1, 2023 with a completion date of July 31, 2026. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through...
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Regents of the University of Minnesota was awarded a $1,202,776 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2027 to map elements of DNA architecture responsible for malignant transformation in craniospinal sarcoma. Through this award, the University of Minnesota will conduct biomedical research to identify medical solutions for battlefield...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
The University of Minnesota was awarded a three-year, $556,454 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to define the relative contributions of K27 methylation and S31 phosphorylation to gliomagenesis in diffuse intrinsic pontine glioma (DIPG). Through September 2022 to August 2025, University researchers will investigate medical solutions for brain tumors on the...
This $1,618,500.00 Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research to transform healthcare for military service members and the broader public. The grant, awarded to the Regents of the University of Minnesota, Office of Sponsored Projects Administration on June 1, 2025, will fund a 3-year research project titled "Targeting eIF4F Complex-Driven...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This $1,539,818.00 Department of the Army Medical Command federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420) will fund research led by the Regents of the University of Minnesota to develop multiplex edited, dual CAR gamma delta T cells targeting pediatric solid tumors. The three-year project, with a performance period from November 15, 2024 to November 14, 2027, seeks to advance innovative cell-based immunotherapies for the treatment of...